FORT LEE, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating ...

Even in death, cells leave a trace. Scientists have discovered a microscopic “Footprint of Death” that not only helps the immune system clean up but can also give viruses a new way to spread infection ...

Aberrations in fibroblast growth factor receptors FGFR2/3 are major drivers of many cancers-including intrahepatic cholangiocarcinoma, endometrial, breast, gastric, and bladder cancers. However, the ...

A laboratory on Long Island has found a breakthrough in the fight against pancreatic cancer that can “intercept” its spread. Now Amy Pollaci, whose father Bill Reindl was diagnosed with stage 4 ...

Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent type of pancreatic cancer, characterized as a highly lethal malignancy that is often preceded by precancerous lesions. These lesions are ...

Revised: This Reviewed Preprint has been revised by the authors in response to the previous round of peer review; the eLife assessment and the public reviews have been updated where necessary by the ...

Bottom line: Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein, and FGFR2 ...

Bottom Line: Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein, and FGFR2 ...

A new study explores the potential of fibroblast growth factor receptor (FGFR) antagonists in restoring defective mandibular bone repair in mouse models of osteochondrodysplasia, a group of genetic ...

A phase IIa clinical trial of first-line cyclical therapy alternating gemcitabine, cisplatin, and durvalumab with pemigatinib for advanced biliary tract cancers with FGFR2-alterations. This is an ASCO ...

Based on the perceived low efficacy of current therapies targeted to FGFR2 in gastric cancer (GC), the authors investigate an approach which combines SHP2 inhibition with existing FGFR2 inhibitors.